

Production of sHLA-G molecules by *in vitro* matured cumulus-oocyte complex

ROBERTA RIZZO^{1*}, MARIA BEATRICE DAL CANTO^{2*}, MARINA STIGNANI¹, RUBENS FADINI², DANIELA FUMAGALLI², MARIO MIGNINI RENZINI², MONICA BORGATTI³, ROBERTO GAMBARI³ and OLAVIO ROBERTO BARICORDI¹

¹Department of Experimental and Diagnostic Medicine, Laboratory of Immunogenetics, University of Ferrara, Via Luigi Borsari, 46-44100 Ferrara; ²Biogenesi Reproductive Medicine Centre, Istituti Clinici Zucchi, Via Zucchi, 24-20052 Monza; ³ER-GenTech, Department of Biochemistry and Molecular Biology, University of Ferrara, Via Fossato di Mortara, 74-44100 Ferrara, Italy

Received March 3, 2009; Accepted May 25, 2009

DOI: 10.3892/ijmm_00000261

Abstract. Oocyte selection with the highest competence is a major goal in IVF. Several studies demonstrated that non-classical HLA class I HLA-G molecule modulation creates a tolerogenic microenvironment at the feto-maternal interface and is implicated in embryo implantation. This study investigated if soluble HLA-G molecules produced by the cumulus-oocyte complex (COC) are markers of oocyte maturation. sHLA-G molecule levels were analyzed using Bio-Plex assay in 152 COC supernatants obtained from 42 women and matured by an '*in vitro* maturation procedure'. The presence of sHLA-G molecules was confirmed by Western blotting technique. The results demonstrate detectable amounts of sHLA-G molecules ranging from 300 to 800 pg/ml in 14/73 (19%) COCs that generated mature oocytes and complete absence of detectable sHLA-G antigens in the supernatants of COCs that corresponded to immature oocytes. The detection of sHLA-G molecules in the COC culture supernatants corresponding to

matured oocytes is proposed to be a marker to identify gametes with higher functionality. This non-invasive marker could be used, in addition to morphological approaches, to reduce the number of fertilized oocytes and transferred embryos.

Introduction

Currently, several oocytes are fertilized during *in vitro* fertilization (IVF) procedures and two or more embryos are transferred to the uterus in order to increase the chance of a pregnancy. However, this approach results in a high number of multiple pregnancies, perinatal mortality and morbidity. The necessity to overcome these risks together with the presence of ethical problems increases the interest in selecting gametes with the highest competency. This point is of extreme interest in Italy, where the law 40/2004 states that no more than three embryos can be created at any one time and all embryos obtained must be transferred together even if the couple does not need all the embryos (1). In this context the identification of validated markers for oocyte selection represents a fundamental step in IVF.

Several studies demonstrated that HLA-G antigen modulation creates, by direct and indirect mechanisms, a tolerogenic microenvironment at the feto-maternal interface (2). HLA-G molecules inhibit, together with HLA-C and -E, the innate natural killer response against cytotrophoblast cells which lack classical HLA class I and II expression (3-5). HLA-G antigens affect the adaptative cellular response inducing the apoptosis of cytotoxic CD8⁺ T lymphocytes (6,7), impairing CD4⁺ T cell functions and preventing dendritic cell maturation (8,9). HLA-G molecules also induce immunosuppressive regulatory T cell development (10,11).

Detectable levels of soluble HLA-G (sHLA-G) molecules in a percentage of follicular fluids (FFs) from patients admitted to IVF procedures were recently reported (12) and granulosa cells were identified as producers of sHLA-G molecules. The granulosa cells which surround the mammalian oocyte are known as the cumulus oophorus. These cells create a structural pathway for cell-to-cell communication (13) where cumulus cells provide several trophic or metabolic factors for the

Correspondence to: Professor Roberto Gambari, ER-GenTech, Department of Biochemistry and Molecular Biology, University of Ferrara, Via Fossato di Mortara, 74-44100 Ferrara, Italy
E-mail: gam@unife.it

Dr Roberto Baricordi, Department of Experimental and Diagnostic Medicine, Laboratory of Immunogenetics, University of Ferrara, Via Luigi Borsari, 46-44100 Ferrara, Italy
E-mail: bri@unife.it

*Contributed equally

Abbreviations: HLA, histocompatibility antigen; IVF, *in vitro* fertilization; COC, cumulus-oocyte complex; FF, follicular fluids; IVM, *in vitro* maturation; PCO, polycystic ovarian syndrome;

Key words: HLA-G, oocyte, *in vitro* maturation

Table I. Details of *in vitro* maturation procedure.

	Women n=42
Age (years) (mean±SD)	35±3
Number of recovered oocytes per woman (mean±SD)	7±1
Mature oocytes per woman (%)	20-50

preovulatory oocyte (14). Several results indicate that the measurement of gene transcription levels in cumulus cells reliably complement the morphological oocyte evaluation providing a useful tool for selecting oocytes with greater chances to be fertilized (15,16).

Considering the presence of sHLA-G in FFs during the oocyte maturation, this study verified if it is a marker of this process. The culture supernatants of 'in vitro matured' oocytes were analyzed for sHLA-G presence. The target of 'in vitro maturation' (IVM) technique is to retrieve immature oocytes from the ovary and to induce their maturation *in vitro*. We employed *in vitro* co-cultures of oocytes and cumulus cells to restore support from the surrounding cumulus cells to the oocyte (17,18). This system allowed us to analyze the sHLA-G production by the cumulus-oocyte complex (COC) without the influence of the *in vivo* maternal microenvironment.

Materials and methods

Patients. The oocytes employed for this study were obtained from regularly cycling patients attending the Biogenesi Reproductive Medicine Centre of Monza, Italy, for an Assisted Reproduction Technique with In Vitro Maturation Protocol (IVM). Couples included in the trial had an indication of the IVF procedure because of infertility due to the male factor, tubal factor, stage I/II endometriosis, polycystic ovarian syndrome (PCO) or unexplained causes. All the women included had regular cycles of 26-35 days. A written informed consent was obtained from all participating couples. We considered just one cycle per couple. After the maturation process we used from one to three oocytes according to the Italian Law 40 on IVF (1). Following these criteria, 42 women were recruited for the study. Characteristics of the female patients are reported in Table I. Oocyte recovery was performed by means of transvaginal ultrasound-guided follicle aspiration, using a single lumen aspiration needle (Gynetics cod. 4551-E2 Ø17-gauge 35 cm) connected to a vacuum pump (Craft Pump pressure 80-90 mmHg). The aspirated FFs, containing COCs, were washed with prewarmed Flushing Medium with heparin (Medi-Cult product no. 10760125, Denmark). The oocytes were detected under a stereomicroscope, examined and classified on the basis of their morphology. Oocytes with signs of mechanical damage or atresia were discarded. Immature COCs were individually cultured in a 4-well culture dish with 0.5 ml of IVM Medium (vial 2 of IVM system medium; Medicult no. 82214010, Denmark) supplemented with rec-FSH 0.075 IU/ml (Serono, Italy), hCG 0.1 IU/ml (Serono, Italy) and

Table II. Mature COC and oocyte grade scoring.

A, COC		
Mature COC grade	Cumulus	Adhesion to oocyte
Grade A	expanded multilayer	full
Grade B	full/spare 1-3 layers	spare

B, Oocyte

Mature oocyte grade	Cytoplasmatic	Polar body
Grade 1	homogenous	round
Grade 2	granular	round
Grade 3	granular	fragmented/irregular

10% serum protein substitute (SPS no. 3010, Sage Media, USA) for 30 h. Following the maturation period, the supernatants were collected from each culture system containing a single COC and stored at -20°C until tested for the presence of sHLA-G. The oocytes were denuded from cumulus and evaluated for the presence of the first polar body to confirm Metaphase II stage. The Metaphase II oocytes were considered mature, while the Metaphase I, degenerated and germinal vesicle oocytes were defined as immature (19). The mature oocytes were classified according to surrounding cumulus cells as follows. Grade A, expanded cumulus with multilayer and slack cumulus cells with a full adhesion to the oocyte with cumulus; Grade B, full or spare compact cumulus with one to three layers of cumulus cells with a spare adhesion to the oocyte (Table IIa); and graded on the first polar body and cytoplasm characteristics. Grade 1, homogeneous cytoplasm and round polar body; Grade 2, oocyte with variations in colour or granularity of the cytoplasm and/or presence of inclusions, vacuoles or retractable bodies, but a round polar body; Grade 3, oocyte with variations in colour or granularity of the cytoplasm and/or presence of inclusions, vacuoles or retractable bodies with a fragmented polar body (Table IIb).

sHLA-G ELISA. sHLA-G1, obtained from the proteolytic cleavage of the membrane bound HLA-G1 and -G5, generated by mRNA alternative splicing, was assayed as reported in Essen Workshop on sHLA-G quantification (20) using as capture antibody the Moab MEM-G9 (Exbio, Prague, Czech Republic), which recognizes HLA-G molecule, in β_2 -microglobulin-associated form, at the concentration of 20 μ g/ml. The anti- β_2 microglobulin Moab-HRP conjugated, (Dako, Glostrup, Denmark) was used as detecting antibody diluted 1:1,000 in PBS1x. HeLa cell wild-type culture supernatants were used as negative control, transfected HeLa-G5 cell (kindly provided by Professor E. Weiss, Institut für Anthropologie und Genetik, LMU, Munich, Germany) as a positive control. Culture supernatants were collected at cell confluence and concentrated by lyophilization procedure. Following depletion

Table III. Calculated standard concentrations from ELISA and BioPlex assays.

A, ELISA assay		
Standard Conc pg/ml	Calculated Conc ^a pg/ml	Error ^b %
800	1035	29.4
500	535	7.0
400	485	21.3
300	435	45.0
Mean error (%)		25.7
B, BioPlex assay		
Standard Conc pg/ml	Calculated Conc ^a pg/ml	Error ^b %
800	798	0.3
500	514	2.6
400	379	5.0
300	315	5.0
200	195	3.0
Mean error (%)		3.2

^aFor the calculated standard concentrations we used the regression curve equations: The r^2 values were 0.9434 and 0.9958 for ELISA and BioPlex assays respectively. ^b%Error, absolute value $\{[(\text{calculated concentration} - \text{standard concentration}) / \text{standard concentration}] \times 100\}$.

of albumin by albumin depletion kit (Enchant Life Science kit, Pall Corporation, MI, USA), the purification of the sHLA-G proteins was carried out as previously reported (21). The sHLA-G molecules obtained were used as standard at different dilutions. COC culture medium was used for standard dilution. Detection limit was calculated with repeated measurements of a negative control obtained with culture medium. This way all the variables of the assay were considered. We calculated the mean of the optical density (OD) value obtained in the negative control wells, present in triplicate in each plate, and a standard deviation (SD), with the value of lower limit of detection being 3.29 SD added to the mean OD value (22). In this case, there is only a 5% chance of classifying a result in the wrong population and the lower limit of detection sample determinations are above this midway concentration with a probability of 95%. The limit of sensitivity is 600 pg/ml.

Bio-Plex system: covalent coupling of antibodies to microspheres. Covalent coupling of anti-sHLA-G antibodies to the carboxylated polystyrene microspheres (Bio-Rad, Hercules, CA, USA) was performed using the Bio-Plex amine coupling kit (Bio-Rad). Briefly, the microspheres stock solution was dispersed by bath sonication until a homogeneous distribution of the microspheres was observed. For a 1x scale coupling

reaction, 100 μ l of monodisperse beads (1.25×10^6 microspheres), were centrifuged at $14,000 \times g$ for 4 min and washed with 100 μ l of bead wash buffer. Bead pellets were resuspended in 80 μ l of bead activation buffer, vortexed for 30 sec, and then sonicated by bath sonication for 30 sec. Solutions of N-hydroxysulfosuccinimide (S-NHS) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) (Pierce Biotechnology, Rockford, IL, USA), both at 50 mg/ml, were prepared in bead activation buffer immediately prior to its use and 10 μ l of each solution was sequentially added to stabilize the reaction and activate the microspheres. This suspension was vortexed for 30 sec and then agitated with a rotator at room temperature for 20 min in the dark. Then activated beads were washed twice with 150 μ l of PBS, pH 7.4, incubated with 5 μ g of Moab MEM-G9 (Exbio) in a final volume of 500 μ l of PBS, pH 7.4 and agitated with a rotator at 4°C overnight in the dark. After washing with 500 μ l of PBS, pH 7.4 beads were resuspended with 250 μ l of blocking buffer and agitated at room temperature for 30 min in the dark. Coupled beads were washed with 500 μ l of storage buffer, resuspended in 150 μ l of storage buffer and counted with a hemacytometer. Coupling efficiency of monoclonal antibodies was tested by staining 10,000 microspheres with a biotinylated antibody directed to the source of the capture antibody (goat anti-mouse immunoglobulin G, e-Bioscience, San Diego, USA) followed by streptavidin-PE for 30 and 10 min at room temperature in the dark respectively. Microspheres, resuspended in 150 μ l of storage buffer, were measured and analyzed with the Bio-Plex system (Bio-Rad).

s-HLAG Bio-Plex assay. COC culture supernatants were assayed for sHLA-G using a bead array system Bio-Plex (Bio-Rad) according to the manufacturer's instructions. Briefly, 50 μ l of sHLA-G standards (prepared in the same fresh culture medium and assayed in duplicate) or samples (COC culture supernatants in duplicate) incubated with 50 μ l of anti-sHLA-G conjugated beads (5000 beads/well) in 96-well filter plates for 60 min at room temperature with shaking. Plates were washed by vacuum filtration three times with 100 μ l of Bio-Plex wash buffer, 25 μ l of biotinylated antibody W6/32 (10 μ g/ml) (Dako) was added, and plates were incubated for 30 min at room temperature with shaking. After three filter washes, 50 μ l of streptavidin-phycoerythrin was added, and the plates were incubated for 15 min at room temperature with shaking. Finally, plates were washed by vacuum filtration three times, beads were suspended in 125 μ l of Bio-Plex assay buffer, and samples were analyzed on the Instrument Bio-Plex system in combination with the Bio-Plex Manager software. The standard curves for sHLA-G were used from 24,000 to 93.75 pg/ml and the minimum detectable dose was 300 pg/ml. The detection limit was calculated with repeated measurements of a negative control obtained with culture medium. We considered all variables of the assay. We calculated the mean of the fluorescence value obtained in negative control wells, present in triplicate in each plate, and SD, with the value of lower limit of detection being 3.29 SD added to the mean FI (22). In this case, there is only a 5% chance of classifying a result in the wrong population and the lower limit of detection sample determinations are above this midway concentration with a probability of 95%. The specificity

of this assay was validated with an isotype control (Mouse IgG1 Isotype control, code 1B-457-C100 Biotin; Exbio) used in the place W6/32 Biotin Moab. The background observed was lower than the selected detection limit (data not shown). We obtained the limit of sensitivity at 300 pg/ml.

Western blotting. The presence of HLA-G molecules in COC supernatants were analysed by denaturing SDS-PAGE in a group of ELISA sHLA-G positive and negative samples (12). Briefly, 100x concentrated and albumin depleted pooled COC supernatants were loaded on 10% SDS-polyacrylamide gel, electrophoresed at 80 V for 2 h and blotted onto PVDF membrane (Immobilon-P Millipore, Billerica, MA, USA) by electrotransfer at 100 V for 45 min in 25 mM Tris Buffer, 190 mM glycine, 2% SDS and (v/v) methanol each. Blocking was carried out with 5% nonfat dry milk, Tris 100 mM pH 7.5, NaCl 150 mM overnight at 4°C. After two washes, the membrane was incubated with MEM-G1 Moab (Exbio) (10 µg/ml), which recognizes HLA-G molecule in denaturated form, for 3 h at room temperature with gentle shaking. The sHLA-G molecules were detected using protein-G HRP (Bio-Rad) at dilution of 1:5,000 in 10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Tween-20. Reactions were developed by chemiluminescence with SuperSignal enhanced chemiluminescence kit (Super Signal West Pico system, Pierce) and captured by Chemiluminescence Imaging Geliance 600 detection system (Perkin-Elmer, CT, USA). Soluble HLA-G molecules, purified as previously reported (sHLA-G ELISA section), were used as positive control, culture medium as negative control. The COC supernatants were loaded at the same total protein concentration that was evaluated by Quick Start Bradford protein assay (Bio-Rad). The molecular weights were determined with the BenchMark (Invitrogen, CA, USA) pre-stained protein ladder (range 10-200 kD).

Statistics. The Fisher's exact test was used to analyze the different frequencies in sHLA-G positivities between COCs that generated mature or immature oocytes. The Correlation Z and Regression tests were used to analyze the interpolation of ELISA and Bio-Plex standard curves. The statistical analysis was conducted using Stat View software package (SAS Institute Inc., Cary, NC, USA). P-value of ≤ 0.05 was considered significant (two tailed).

Results

Comparison between the sHLA-G ELISA and Bio-Plex assays. We compared the Bio-Plex assay and ELISA technique in quantifying sHLA-G molecules. We used the same capture antibody and standard reagents in both techniques in order to maintain the same specificity. They were compared for their sensitivity by geometric dilutions of the sHLA-G standard reagent. In Fig. 1a and b the standard curves of the ELISA and Bio-Plex assays were obtained with 50 µl of standard reagent at the concentrations of 800, 500, 400, 300 pg/ml. The sensitivity was calculated with repeated measurements of a negative control and a 3.29 SD was calculated (22) (see Materials and methods). We interpolated the data in order to obtain a standard curve. The low limit of detection, corresponding to the 3.29 SD added to the mean FI or OD value of the negative control, reached 300 pg/ml in the Bio-Plex assay




Figure 1. ELISA (a) and Bio-Plex (b) standard curves (black line). They were obtained with 50 µl of standard reagent at the concentrations of 800, 500, 400, 300 pg/ml. Detection limit, dotted line, 3.29 SD added to the mean optical density (OD) or fluorescence (FI) of repeated negative control (culture medium) measurements. The bold line indicates the linear regression and the dashed lines the 95% confidence interval. r^2 Values, 0.9434 and 0.9958 for the ELISA and Bio-Plex assays respectively and CV values, 3.1 and 1.7 respectively.

and 600 pg/ml in the ELISA system. We observed a different accuracy in these two assays. As reported in Table III, the Bio-Plex calibration curve described the standard data with the lowest error (mean error, 3.2%) in comparison to ELISA calibration curve (mean error, 25.7%) (23). The coefficient of variation (CV) for the Bio-Plex assay was 1.7 whereas the ELISA presented a CV of 3.1. The statistical analysis of these two calibration curves has a higher correlation in the Bio-Plex standard curve in comparison with ELISA (Correlation Z test, Bio-Plex $p < 0.0001$, $r^2 = 0.9958$; ELISA $p = 0.035$, $r^2 = 0.9434$; Regression test Bio-Plex $p = 0.0001$; ELISA $p = 0.0287$). The low CV error and detection limit associated with the Bio-Plex test indicated to select this assay to analyze the COC culture supernatants in order to reach lower sHLA-G levels with a higher degree of reliability in comparison with the ELISA system. The highest sensitivity of Bio-Plex assay is considered in comparison to our ELISA system and for low sHLA-G concentrations.

Detection of sHLA-G molecules in COC culture supernatants. We analyzed the COC culture supernatants by means of Bio-Plex technology. We analyzed 152 COC supernatants from IVM procedures performed in 42 women. Among the COCs, 73 matured (Metaphase II stage) and 79 remained immature (Prophase I or Metaphase I stage). Each woman had from one to three mature oocytes and from one to two immature oocytes. We revealed sHLA-G levels above 300 pg/ml in 14/73 (19%) COC supernatants that generated mature oocytes (Fig. 2), in a range from 309 to 800 pg/ml, while no sHLA-G was detected in COC supernatants corresponding to immature oocytes ($p = 8.4 \times 10^{-5}$; Fisher exact test). These results




Figure 2. sHLA-G levels in 73 COC culture supernatants that generated mature oocytes. Detection limit, dotted line, 3.29 SD added to the mean fluorescence (FI) of repeated negative control (culture medium) measurements.




Figure 3. Western blot analysis of COC supernatants positive (O1) or negative (O2) for sHLA-G detection by Bio-Plex system. Anti HLA-G1/HLA-G5 MEM-G1 MoAb was used for detection. +, HLA-G purified molecules as positive control; -, culture medium as negative control. The COC supernatants were loaded at the same total protein concentration that was evaluated by Quick Start Bradford protein assay. The molecular weights (Mk) were determined with the BenchMark (Invitrogen, CA, USA) pre-stained protein ladder (range 10-200 kD).

document the presence of sHLA-G molecules only in COCs that produced mature oocytes.

Western blot analysis. We confirmed the data obtained in COC supernatants by Bio-Plex technique with Western blot analysis. In Fig. 3 we show a representative blot with a sHLA-G positive COC supernatant (second lane) and a sHLA-G negative COC supernatant (third lane), confirming the results obtained by Bio-Plex. We considered the upper bands present in all the samples as aspecific positivities and the 37 kD positive band as HLA-G specific.

sHLA-G molecules and mature COC characteristics. The variability in sHLA-G levels could be associated with different oocyte characteristics. We evaluated the morphological feature of mature COCs (Table I). Taking into consideration the surrounding cumulus cell feature, we observed no differences in the percentage of sHLA-G positive supernatants in Grade A mature COCs (expanded cumulus) (9/43; 21%) in comparison to Grade B COCs (full or spare cumulus) (5/30; 17%) ($p=NS$, Fisher exact test) (Table IV; Fig. 4a). Considering the polar

Table IV. Subdivision of mature oocytes accordingly to COC and oocyte grading and sHLA-G production.

	Mature oocyte (n=73)	sHLA-G+ (n=14)
COC grade		
Grade A	43	9
Grade B	30	5
Oocyte grade		
Grade 1	22	8
Grade 2	15	1
Grade 3	36	5




Figure 4. sHLA-G levels in mature COC supernatants subdivided accordingly to a) COC feature (Grade A and B); b) characterization of oocyte polar body and cytoplasm (Grade 1, 2 and 3). Detection limit, dotted line, 3.29 SD added to the mean fluorescence (FI) of repeated negative control (culture medium) measurements.

body and cytoplasmic morphological characteristics of mature oocytes (Metaphase II), evaluated after cumulus removal, we observed a difference in the percentage of sHLA-G positive COC supernatants which correspond to Grade 1 oocytes (8/22; 36%) in comparison to Grade 2 (1/15; 7%) ($p=0.056$, Fisher exact test) and Grade 3 (5/36; 14%) ($p=0.058$, Fisher exact test) (Table IV; Fig. 4b). The increased ability of COCs that generated Grade 1 oocytes to produce sHLA-G molecules is near the significant statistical p -value, probably because of the small number of samples. However, the clear tendency of mature COCs with high score oocytes to produce more sHLA-G molecules, proposes that these molecules are markers of oocyte grade. Therefore, increasing the number of analyzed COCs would confirm this observation.

sHLA-G molecules in mature COC culture supernatants subdivided between women. In order to identify a possible different sHLA-G production between the mature COCs of




Figure 5. sHLA-G levels in mature COC supernatants subdivided into women (a) and in 10 representative women with oocyte Grade (grade 1, black; grade 2, grey and grade 3, white). Detection limit, dotted line, 3.29 SD added to the mean fluorescence (FI) of repeated negative control (culture medium) measurements.

the same woman, we subdivided them between women (Fig. 5a). The 14 supernatants with sHLA-G positivity corresponded to 13 different women. Taking into consideration the women with at least one sHLA-G positive COC culture, we observed different sHLA-G levels in their COC supernatant. For example, in Fig. 5a, woman number 1 presents two COC supernatants with no sHLA-G and one with 410 pg/ml of sHLA-G; woman number 10 has all three COC cultures negative for sHLA-G detection. The women presented different sHLA-G levels when we compared COC supernatants between women. These data are of great interest because COCs could be characterized by a different ability to produce HLA-G molecules. Taking into consideration the previous results on oocyte morphology and differences in sHLA-G modulation, we analyzed if the differences in sHLA-G levels between women correlate to different oocyte Grades. In Fig. 5b we show 10 representative women. There is an association between the differences observed in sHLA-G levels and the oocyte Grades. Woman number 1 has two COC supernatants without sHLA-G classified as Grade 3 (white), and Grade 2 (grey) and one with 410 pg/ml of sHLA-G Grade 1 (black); woman number 10 has all three COC cultures negative for sHLA-G and Grade 3 oocytes.

Discussion

The reduction of the number of fertilized oocytes and transferred embryos is the main target of assisted reproductive medicine. During recent years, several studies suggested a relationship between the production of sHLA-G molecules by early embryos and an increased implantation rate in IVF protocols (24-35,12). Two studies (36,37) failed to detect sHLA-G molecules in embryo culture supernatants, probably due to technical discrepancies, as suggested by the recent review by Warner *et al* (38). It is important to develop a very high quality level in sHLA-G detection methodology to

overcome these problems in order to evaluate the exact amount of sHLA-G produced by an *in vitro* cultured embryo (39) and to establish the functional role of sHLA-G during early embryo development (40). However, data obtained by twelve researches suggest the production of sHLA-G as a marker of embryo implantation. It is still mandatory to evaluate embryo morphological parameters for an accurate embryo selection.

Oocytes obtained under ovarian stimulation present a variable competence and although molecular approaches have been proposed (41,42) the selection is still performed on morphological characteristics. Recently, the presence of sHLA-G molecules in a percentage of FFs and a significant association with the production of these antigens by the corresponding fertilized oocyte was reported (12). Shaikly and coauthors (35) confirmed the presence of sHLA-G molecules in FFs but they failed to identify the correlation with early embryo sHLA-G production. Several differences in embryo culture conditions and in the technical procedures to detect sHLA-G could justify the different results obtained by these two studies. The presence of sHLA-G in FFs is not a confirmation that it is important in oocyte maturation but it seems to be a marker of embryo competency. However, further studies are required to confirm the relationship between FFs and embryo sHLA-G production. The goal of this study was to identify if sHLA-G is also a marker of oocyte maturation. The oocyte maturity was demonstrated to be important in producing good quality blastocysts for embryo transfer (19) and molecular markers. To define oocyte maturity would be of great interest together with morphological characterization. A sHLA-G assay based on Luminex technology reaching a detection limit of 300 pg/ml was proposed (34). We developed a similar Bio-Rad's Bio-Plex system reaching the same limit of sensitivity.

Our results show that COCs produce sHLA-G molecules during the oocyte maturation process. The main point is that no sHLA-G molecules were detected in the COC culture supernatants corresponding to immature oocytes. Some COCs produced mature oocytes but no sHLA-G was observed in their supernatants, underlining that sHLA-G is only one of the factors implicated in this process. Overall these results suggest a variable production of sHLA-G molecules in association with a different oocyte maturation. sHLA-G production was related to the morphological characteristics of mature COCs in order to analyze the possible functional role of these differences. All mature COCs were classified accordingly to their granulosa cell morphology, and to the oocyte cytoplasm and polar body characteristics before insemination. Taking into consideration the surrounding cumulus cell feature, we observed similar percentages of sHLA-G positive supernatants in Grade A and B mature COCs (Fig. 4a). On the contrary, the classification using polar body and cytoplasm characteristics demonstrated a tendency of Grade 1 mature oocytes to produce sHLA-G molecules higher than Grade 2 and 3 oocytes (Fig. 4b). This association proposes sHLA-G as a marker to identify high score mature oocytes. It is mandatory to increase the number of analyzed oocytes in order to confirm our observation based on a statistical significance near the p-value limit. The analysis of sHLA-G concentrations in mature COCs between women shows different sHLA-G levels both in mature COCs from the same woman and from different women. These data confirm

that COCs are characterized by a different ability to produce sHLA-G molecules that is associated with the different oocyte grade.

Further analyses are required to define the mechanisms that influence sHLA-G production and the role of this antigen as directly implicated in oocyte maturation or as a marker of COC metabolism. A metabolic cooperation between oocyte and the surrounding granulosa cells is required for a complete maturation. The absence of sHLA-G molecules in immature COCs suggests a role for these molecules in oocyte maturation. It is known that cumulus cells express innate immune related genes (CD14, Toll-like receptors) (43) that play critical roles in surveillance and cell survival during the ovulation process and HLA-G could be one of these mechanisms. sHLA-G could be important in the maintenance of a balance between pro- and anti-inflammatory effectors and the absence of this molecule in COC supernatants could identify a difficulty in creating the correct maturation microenvironment.

In conclusion, these data demonstrate, for the first time, the ability of mature COCs to produce detectable amounts of sHLA-G molecules. This production could be a marker of good quality oocyte maturation and used to select the best oocyte to be fertilized in addition to the morphological approaches in order to reduce the number of produced and transferred embryos.

Acknowledgements

We thank Dr Amanda Neville for her writing assistance. R.G. is recipient of grants from Fondazione Cariparo (Cassa di Risparmio di Padova e Rovigo), CIB, UE eInfrastructure for the Thalassemia Research Network (ITHANET) Project, Telethon (contract GGP07257), COFIN-2007, EU Project COCHISE and Associazione Veneta per la Lotta alla Talassemia (AVLT), Rovigo.

References

1. Fineschi V, Neri M and Turillazzi E: The new Italian law on assisted reproduction technology. *J Med Ethics* 31: 536-539, 2005.
2. Rouas-Freiss N, Naji A, Durrbach A and Carosella ED: Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. *Transplantation* 84: S21-S25, 2007.
3. Moffett A and Loke C: Immunology of placentation in eutherian mammals. *Nat Rev Immunol* 6: 584-594, 2006.
4. Khalil-Daher I, Riteau B, Menier C, Sedlik C, Paul P, Dausset J, Carosella ED and Rouas-Freiss N: Role of HLA-G versus HLA-E on NK function: HLA-G is able to inhibit NK cytotoxicity by itself. *J Reprod Immunol* 43: 175-182, 1999.
5. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J and Carosella ED: Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytotoxicity. *Proc Natl Acad Sci USA* 94: 11520-11525, 1997.
6. LeGal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED and Rouas-Freiss N: HLA-G mediated inhibition of antigen-specific cytotoxic T lymphocytes. *Int Immunol* 11: 1351-1356, 1999.
7. Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, Bensussan A and Le Bouteiller P: Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8⁺ cells by interacting with CD8. *J Immunol* 164: 6100-6104, 2000.
8. Bainbridge DR, Ellis SA and Sargent IL: HLA-G suppresses proliferation of CD4⁺ T-lymphocytes. *J Reprod Immunol* 48: 17-26, 2000.
9. Lila N, Rouas-Freiss N, Dausset J, Carpentier A and Carosella ED: Soluble HLA-G protein secreted by allo-specific CD4⁺ T cells suppresses the allo-proliferative response: a CD4⁺ T cell regulatory mechanism. *Proc Natl Acad Sci USA* 98: 12150-12155, 2001.
10. Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A and Wiendl H: HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. *Blood* 110: 568-577, 2007.
11. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED and Deschaseaux F: Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4⁺CD25^{high}FOXP3⁺ regulatory T cells. *Stem Cells* 26: 212-222, 2008.
12. Rizzo R, Fuzzi B, Stignani M, Criscuoli L, Melchiorri L, Dabizzi S, Campioni D, Lanza F, Marzola A, Branconi F, Noci I and Baricordi OR: Soluble HLA-G molecules in follicular fluid: a tool for oocyte selection in IVF? *J Reprod Immunol* 74: 133-142, 2007.
13. Gilchrist RB, Ritter LJ and Armstrong DT: Oocyte-somatic cell interactions during follicle development in mammals. *Anim Reprod Sci* 82-83: 431-446, 2004.
14. Elvin JA, Clark AT, Wang P, Wolfman NM and Matzuk MM: Paracrine actions of growth differentiation factor-9 in the mammalian ovary. *Mol Endocrinol* 13: 1035-1048, 1999.
15. Feuerstein P, Cadoret V, Dalbès-Tran R, Guerif F, Bidault R and Royere D: Gene expression in human cumulus cells: one approach to oocyte competence. *Hum Reprod* 22: 3069-3077, 2007.
16. Cillo F, Brevini TA, Antonini S, Paffoni A, Ragni G and Gandolfi F: Association between human oocyte developmental competence and expression levels of some cumulus genes. *Reproduction* 134: 645-650, 2007.
17. Combelles CM, Cekleniak NA, Racowsky C and Albertini DF: Assessment of nuclear and cytoplasmic maturation in in-vitro matured human oocytes. *Hum Reprod* 17: 1006-1016, 2002.
18. Eppig JJ: Intercommunication between mammalian oocytes and companion somatic cells. *Bioessays* 13: 569-574, 1991.
19. Huang FJ, Huang HW, Lan KC, Kung FT, Lin YC, Chang HW and Chang SY: The maturity of human cumulus-free oocytes is positively related to blastocyst development and viability. *J Assist Reprod Genet* 19: 555-560, 2002.
20. Rebmann V, Lemaout J, Rouas-Freiss N, Carosella ED and Grosse-Wilde H: Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen. *Human Immunol* 66: 853-863, 2005.
21. LeFric G, Laupeze B, Fardel O, Sebti Y, Pangault C, Guilloux V, Beauplet A, Fauchet R and Amiot L: Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. *Hum Immunol* 64: 752-761, 2003.
22. Anderson DJ: Determination of the lower limit of detection. *Clin Chem* 35: 2152-2153, 1989.
23. Plikaytis BD, Turner SH, Gheesling LL and Carlone GM: Comparisons of standard curve-fitting methods to quantitate *Neisseria meningitidis* group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. *J Clin Microbiol* 29: 1439-1446, 1991.
24. Fuzzi B, Rizzo R, Criscuoli L, Noci I, Melchiorri L, Scarselli B, Bencini E, Menicucci A and Baricordi OR: HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. *Eur J Immunol* 32: 311-315, 2002.
25. Roussev RG, Keskinetepe L and Coulam CB: Soluble HLA-G (sHLA-G) in human embryo culture media: a useful marker for assessing embryo quality and implantation potential for IVF. *Fertil Steril* 80: S12-S13, 2003.
26. Sher G, Keskinetepe L, Nouriani M, Roussev R and Batzofin J: Expression of sHLA-G in supernatants of individually cultured 46-h embryos: a potentially valuable indicator of 'embryo competency' and IVF outcome. *Reprod Biomed Online* 9: 74-78, 2004.
27. Criscuoli L, Rizzo R, Fuzzi B, Melchiorri L, Menicucci A, Cozzi C, Dabizzi S, Branconi F, Evangelisti P, Baricordi OR and Noci I: Lack of histocompatibility leukocyte antigen-G expression in early embryos is not related to germinal defects or impairment of interleukin-10 production by embryos. *Gynecol Endocrinol* 20: 264-269, 2005.
28. Noci I, Fuzzi B, Rizzo R, Melchiorri L, Criscuoli L, Dabizzi S, Biagiotti R, Pellegrini S, Menicucci A and Baricordi OR: Embryonic soluble HLA-G as a marker of developmental potential in embryos. *Hum Reprod* 20: 138-146, 2005.
29. Sher G, Keskinetepe L, Batzofin J, Fisch J, Acacio B, Ahlering P, and Ginsburg M: Influence of early ICSI-derived embryo sHLA-G expression on pregnancy and implantation rates: a prospective study. *Hum Reprod* 20: 1359-1363, 2005.

30. Sher G, Keskinetepe L, Fisch JD, Acacio BA, Ahlering P, Batzofin J and Ginsburg M: Soluble human leukocyte antigen G expression in phase I culture media at 46 h after fertilization predicts pregnancy and implantation from day 3 embryo transfer. *Fertil Steril* 83: 1410-1414, 2005.
31. Yie SM, Balakier H, Motamedi G and Librach CL: Secretion of human leukocyte antigen-G by human embryos is associated with a higher in vitro fertilization pregnancy rate. *Fertil Steril* 83: 30-36, 2005.
32. Desai N, Filipovits J and Goldfarb J: Secretion of soluble HLA-G by day 3 human embryos associated with higher pregnancy and implantation rates: assay of culture media using a new ELISA kit. *Reprod Biomed Online* 13: 272-277, 2006.
33. Fisch JD, Keskinetepe L, Ginsburg M, Adamowicz M and Sher G: Graduated Embryo Score and soluble human leukocyte antigen-G expression improve assisted reproductive technology outcomes and suggest a basis for elective single-embryo transfer. *Fertil Steril* 87: 757-763, 2007.
34. Rebmann V, Switala M, Eue I, Schwahn E, Merzenich M and Grosse-Wilde H: Rapid evaluation of soluble HLA-G levels in supernatants of in vitro fertilized embryos. *Human Immunol* 68: 251-258, 2007.
35. Shaikly VR, Morrison IE, Taranissi M, Noble CV, Withey AD, Cherry RJ, Blois SM and Fernández N: Analysis of HLA-G in maternal plasma, follicular fluid, and preimplantation embryos reveal an asymmetric pattern of expression. *J Immunol* 180: 4330-4337, 2008.
36. Van Lierop MJ, Wijnands F, Loke YW, Emmer PM, Lukassen HG, Braat DD, van der Meer A, Mosselman S and Joosten I: Detection of HLA-G by a specific sandwich ELISA using monoclonal antibodies G233 and 56B. *Mol Hum Reprod* 8: 776-784, 2002.
37. Sageshima N, Shobu T, Awai K, Hashimoto H, Yamashita M, Takeda N, Odawara Y, Nakanishi M, Hatake K and Ishitani A: Soluble HLA-G is absent from human embryo cultures: a reassessment of sHLA-G detection methods. *J Reprod Immunol* 75: 11-22, 2007.
38. Warner CM, Lampton PW, Newmark JA and Cohen J: Soluble human leukocyte antigen-G and pregnancy success. *Reprod Biomed Online* 17: 470-485, 2008.
39. Menezo Y, Elder K and Viville S: Soluble HLA-G release by the human embryo: an interesting artefact? *Reprod Biomed Online* 13: 763-764, 2006.
40. Apps R, Gardner L and Moffett A: A critical look at HLA-G. *Trends Immunol* 29: 313-321, 2008.
41. Coticchio G, Sereni E, Serrao L, Mazzone S, Iadarola I and Borini A: What criteria for the definition of oocyte quality? *Ann NY Acad Sci* 1034: 132-144, 2004.
42. Patrizio P, Fragouli E, Bianchi V, Borini A and Wells D: Molecular methods for selection of the ideal oocyte. *Reprod Biomed Online* 15: 346-353, 2007.
43. Liu Z, Shimada M and Richards JS: The involvement of the Toll-like receptor family in ovulation. *J Assist Reprod Genet* 25: 223-228, 2008.